Laura Joszt, MA

The latest piece in HHS’ roadmap to move the healthcare industry to value-based payments is the Accountable Health Communities model. Here are 5 things to know about how this model addresses social determinants of health.

The annual Clinical Cancer Advances report from the American Society of Clinical Oncology highlights the accomplishments made in the last year in the fight against cancer.

Study finds a link between maternal obesity and diabetes and a significant increase in the risk of autism spectrum disorder in children.

CMS has proposed changes to accountable care organizations benchmarks in the Medicare Shared Savings Program, as well as a way to better facilitate the transition to performance-based risk.

For the second year, Anthony D. Slonim, MD, DrPH, is in the running for Modern Healthcare’s 50 Most Influential Physician Executives and Leaders. Recently, he discussed what it means to be a physician leader, the industry’s move to population health, and more.

In an effort to address safety concerns regarding severe neutropenia, the FDA has made changes to requirements for monitoring prescribing, dispensing, and receiving the schizophrenia medicine clozapine.

As Americans as asked to pay a greater portion of their healthcare expenditures, new insurance design models are being implemented, such as value-based insurance design, to combat issues like nonadherence.

After pressure from insurers over concerns of rising costs, the government is eliminating several special open enrollment periods and will provide stronger enforcement of the remaining special open enrollment periods.

Just hours before Bernie Sanders (I-VT) took the stage to face off against Hillary Clinton for the last Democratic presidential debate before the Iowa caucus, the senator released an outline of his single-payer healthcare plan.

The digital health panel at the JP Morgan Healthcare Conference analyzed how the industry can move from collecting data to turning it into actionable and useful information.

Ahead of the president’s final State of the Union address, Democrats announced new plans to investigate drug prices in 2016.

Robert Califf, MD, just unanimously won the Senate panel vote for advance his nomination for FDA commissioner. Now the nomination goes to the full Senate.

Medicare's accountable care organization (ACO) initiatives now include a total of 477 participants across 4 different model types, including the 21 just announced as part of the new Next Generation ACO Model.

Before the House of Representatives had even passed the bill that guts the Affordable Care Act, President Obama had already announced he would veto it. And now he has made good on that promise.

More than 5 years after the Affordable Care Act was passed, Republicans are sending a bill to unravel the healthcare law to the president's desk. President Obama has already vowed to veto the bill.

A new 5-year program has been created to focus on the health-related social needs of Medicare and Medicaid beneficiaries.

The country’s top insurance lobbying group is losing another big member as Aetna has decided not to renew its membership with America's Health Insurance Plans.

While the prevalence of problems paying medical bills may be greater in certain groups compared with others, almost anyone can experience difficulty paying medical bills, according to the results of a survey from Kaiser Family Foundation/New York Times.

Bundled payments may be part of the future in healthcare’s move to value-based care, but this payment scheme runs into the challenge of penalizing providers for factors that are beyond their control, explained Joshua T. Cohen, PhD, research associate professor of medicine at Tufts Medical Center.

During the last month of 2015, The American Journal of Managed Care asked readers to choose what they thought was the top healthcare story from the year. Options included overall themes from the year and specific events.

KaloBios Pharmaceuticals has taken multiple hits after CEO Martin Shkreli's arrest on December 17. Now it has filed for Chapter 11 bankruptcy.

The most read articles from The American Journal of Accountable Care explore the future of healthcare delivery as the United States moves to value-based care.

The rising cost of drugs was in the spotlight in 2015, and the manuscripts in The American Journal of Pharmacy Benefits highlights the growing concerns of the healthcare industry in regards to rising expenditures.

Although rivaroxaban was approved by the FDA in 2012, there has remained a knowledge gap about how it works with cancer patients. A recent study found that the therapy is safe and effective when used among patients with cancer.

Despite the fact that warfarin is more easily reversible, bleeding complications with the therapy are associated with longer stays in the hospital and higher mortality than dabigatran and rivaroxaban.

Research on the post-marketing surveillance of rivaroxaban found that the drug was as safe as determined from the results of the anticoagulant’s randomized controlled trial.

An analysis revealed growing evidence of improved access to and affordability of care after the implementation of the Affordable Care Act, but gaps remain, especially for low-income adults.

During 2015, the most popular papers published by The American Journal of Managed Care included studies on predicting adherence, engaging members and providers in chronic care management programs, care fragmentation among chronically ill patients, and using behavioral health interventions to improve outcomes and reduce costs.

Patients with atrial fibrillation and renal disease who were treated with rivaroxaban (Xarelto) had less of a risk of fatal bleeding, according to a study presented at the American Heart Association Scientific Session.

Physicians are sticking with what they know when it comes to prescribing treatment for deep vein thrombosis and pulmonary embolism. Researchers found that the most common treatment remains parenteral anticoagulant with warfarin despite the arrival of a the new treatment option rivaroxaban.